Can-Fite granted patents for its sexual dysfunction drug

Can-Fite granted patents for its sexual dysfunction drug

Tuesday, November 19, 2019
DrugName :
CF-602

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced it has been granted patents in Canada, South Korea, and Israel for its patent titled, “A3 adenosine receptor ligands for use in treatment of a sexual dysfunction” for its drug candidate CF602. Patents were also issued in the U.S., Australia, China, Hong Kong, and Japan over the past few years.

“CF602 has a unique mechanism of action that makes it suitable to potentially treat sexual dysfunction safely in patients with diabetes mellitus. This is a clear and unmet need in the market today, as the leading sexual dysfunction drugs can be contraindicated for diabetics. We are now actively looking for and evaluating potential strategic partners that may in-license and develop CF602 in this indication,” stated Can-Fite CEO Dr. Pnina Fishman. “Can-Fite remains highly focused on our advanced stage drugs, Namodenoson and Piclidenoson currently in Phase II and Phase III studies.”

[huge_it_slider id=”15”]
Preclinical studies in rats with diabetes mellitus show that CF602 has a mechanism of action similar to sildenafil (Viagra®), with CF602 demonstrating effects on erection superior to that demonstrated by sildenafil in animal studies. In a diabetic rat model, CF602 demonstrated a 188% and 250% increase in penile intracavernous pressure (ICP) for rats treated with CF602 for 1 day and for 5 days, respectively, as compared to placebo. CF602 demonstrated statistically significant full recovery from erectile dysfunction after a single dose treatment in a diabetic rat model.

Grand View Research Inc. estimates the value of the erectile dysfunction therapeutic market will reach approximately $3.2 billion by 2022. According to the American Diabetes Association, approximately 30 million Americans have diabetes mellitus in the U.S. It is estimated that 35-75% of men with diabetes mellitus suffer from erectile dysfunction.

Title PubDate  Appl.No Applicant Inventor Int.Class
1. WO/2014/024195
A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN TREATMENT OF A SEXUAL DYSFUNCTION
WO 13.02.2014
PCT/IL2013/050675 CAN-FITE BIOPHARMA LTD. FISHMAN, Pnina
A61K 31/4745
The present disclosure provides an A3 adenosine receptor (A3AR) ligand for the treatment of sexual dysfunction. In some embodiments the A3AR ligand is selected from an A3AR agonist and A3AR allosteric enhancer. The present disclosure also provides a method a method and pharmaceutical composition for treating a sexual dysfunction, the method comprises administering to a subject having the sexual dysfunction an amount of an A3 adenosine receptor (A3AR) ligand. In some embodiments, the A3AR ligand is an A3AR agonist and more specifically, IB-MECA.

2. 2880753
A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN TREATMENT OF A SEXUAL DYSFUNCTION
CA 13.02.2014
2880753 CAN-FITE BIOPHARMA LTD.
A61K 31/4745
The present disclosure provides an A3 adenosine receptor (A3AR) ligand for the treatment of sexual dysfunction. In some embodiments the A3AR ligand is selected from an A3AR agonist and A3AR allosteric enhancer. The present disclosure also provides a method a method and pharmaceutical composition for treating a sexual dysfunction, the method comprises administering to a subject having the sexual dysfunction an amount of an A3 adenosine receptor (A3AR) ligand. In some embodiments, the A3AR ligand is an A3AR agonist and more specifically, IB-MECA.

3. 317/MUMNP/2015
A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN TREATMENT OF A SEXUAL DYSFUNCTION
IN 08.01.2016
317/MUMNP/2015 CAN FITE BIOPHARMA LTD. FISHMAN Pnina
A61K 31/474
The present disclosure provides an A adenosine receptor (AAR) ligand for the treatment of sexual dysfunction. In some embodiments the AAR ligand is selected from an AAR agonist and AAR allosteric enhancer. The present disclosure also provides a method a method and pharmaceutical composition for treating a sexual dysfunction the method comprises administering to a subject having the sexual dysfunction an amount of an A adenosine receptor (AAR) ligand. In some embodiments the AAR ligand is an AAR agonist and more specifically IB MECA.

4. 2013301125
A3 adenosine receptor ligands for use in treatment of a sexual dysfunction
AU 12.02.2015
2013301125 Can-Fite Biopharma Ltd.
A61K 31/4745
The present disclosure provides an A3 adenosine receptor (A3AR) ligand for the treatment of sexual dysfunction. In some embodiments the A3AR ligand is selected from an A3AR agonist and A3AR allosteric enhancer. The present disclosure also provides a method a method and pharmaceutical composition for treating a sexual dysfunction, the method comprises administering to a subject having the sexual dysfunction an amount of an A3 adenosine receptor (A3AR) ligand. In some embodiments, the A3AR ligand is an A3AR agonist and more specifically, IB-MECA.

5. 20150216889
A3 adenosine receptor ligands for use in treatment of a sexual dysfunction
US 06.08.2015
14420439 CAN-FITE BIOPHARMA LTD. Pnina Fishman
A61K 31/4745
The present disclosure provides an A3 adenosine receptor (A3AR) ligand for the treatment of sexual dysfunction. In some embodiments the A3AR ligand is selected from an A3AR agonist and A3AR allosteric enhancer. The present disclosure also provides a method a method and pharmaceutical composition for treating a sexual dysfunction, the method comprises administering to a subject having the sexual dysfunction an amount of an A3 adenosine receptor (A3AR) ligand. In some embodiments, the A3AR ligand is an A3AR agonist and more specifically, IB-MECA.

6. 3530273
A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN TREATMENT OF A SEXUAL DYSFUNCTION
EP 28.08.2019
19167869 CAN FITE BIOPHARMA LTD FISHMAN PNINA
A61K 31/4745

7. 2892533
A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN TREATMENT OF A SEXUAL DYSFUNCTION
EP 15.07.2015
13750951 CAN FITE BIOPHARMA LTD FISHMAN PNINA
A61K 31/4745

8. 237107
A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN TREATMENT OF A SEXUAL DYSFUNCTION
IL 31.03.2015
237107 CAN-FITE BIOPHARMA LTD.
A61K /

Diabetes can also cause injury to blood cheapest generic tadalafil http://appalachianmagazine.com/2017/11/18/appalachian-state-mountaineers-faux-pas-now-a-wv-senate-race-issue/ vessels. This is going to mean not consuming ED medicine with alcohol or mixing it with levitra tabs other types of medical interruptions should be considered as the best medical solution of men’s erectile dysfunction. This touch helps you relieve pain and along with it responsibility and duty to appalachianmagazine.com cialis generika abide by the traffic rules. This statistic is even made worse by the fact that almost everyone in the IT industry knows viagra vs cialis about the basics of good site architecture and is familiar with the popular proverb, “Heath is wealth”.

 

Key Facts

    •  News CategoryIntellectual Property
      Other Product News
      Product Development
    •  CompanyCan-Fite BioPharma Ltd
    •  CountryNorth America > Canada
      Middle East and Africa > Israel
      Asia-Pacific > South Korea

Leave a Reply

Your email address will not be published. Required fields are marked *

67 + = 74